Trial Profile
Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms Botulinum toxin-A versus tolterodine for idiopathic overactive bladder; OVERT
- 10 Sep 2018 Status changed from recruiting to completed.
- 04 Dec 2015 Accrual to date is 15% according to United Kingdom Clinical Research Network record
- 12 Nov 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record